<DOC>
	<DOCNO>NCT02891369</DOCNO>
	<brief_summary>The refractory malignant ascites complication advance stage many cancer type . It characterize clinically abdominal pressure sensation , shortness breath pelvic pain . Thus , contributes decrease quality life patient palliative care . Conventional treatment base paracentesis ascites . The progression disease lead increase production ascites require frequent paracentesis . Main therapeutic alternative constitute controversial use diuretic use antibody inhibiting activity Vascular Endothelial Growth Factor ( VEGF ) : bevacizumab . Catumaxomab , monoclonal antibody anti-EpCAM CD3 , develop treatment refractory malignant ascites show sufficient clinical benefit . VEGF overexpressed many tumor . VEGF cause increase capillary permeability capillary filtration surface generate increase protein extravasation . These phenomenon responsible increase volume ascites product . Thus use inhibitor VEGF , bevacizumab , could reduce production ascites . The efficacy bevacizumab decrease volume ascites product demonstrate small animal intraperitoneal administration . Studies humans dos use consistent one study another .</brief_summary>
	<brief_title>Retrospective Analysis Patients Treated With Bevacizumab GHPSJ Intraperitoneal Treatment Refractory Malignant Ascites</brief_title>
	<detailed_description>Main objective / secondary : The objective study describe population , adverse effect , volume ascites product time paracentesis patient receive bevacizumab intraperitoneal refractory malignant ascites . Methodology : This retrospective study mono centric non-interventional . data collect - Name , - date birth , - date number injection bevacizumab dose - side effect , - type cancer , TNM classification , - ascites volume collect paracentesis prior introduction IP bevacizumab , - frequency paracentesis introduction IP bevacizumab , - ascites volume collect paracentesis introduction IP bevacizumab , - frequency paracentesis introduction IP bevacizumab , - albumin - Number line chemotherapy receive - Treatment monotherapy combination chemotherapy - WHO Stadium course - Date death support - Data collection CHIMIO® software DxCare® non-computerized patient record . - Series anonymized patient data Excel® Circulation mode data process opposition patient The anonymous data enter computer file centralize within pharmacy department investigator Groupe Hospitalier Saint Joseph Paris , Carole METZ , process locally . For statistical analysis , quantitative variable express mean , standard deviation , minimum maximum value appropriate . The variable express number percentage . Descriptive data analyzes , correlation study variable specific test determine prognostic value variable use . This single-center retrospective cohort within GHPSJ . Patients aware potential use data file medical research information contain handbook institution patient . Development study : - The list patient receive bevacizumab injection obtain CHIMIO® software . - The data collect validated multidisciplinary way oncologist pharmacist . - Collection analysis data internal pharmacy computerized patient record ( DxCare® ) computerize .</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>All assign patient receive least one injection bevacizumab intraperitoneal within GHPSJ 01/01/2007 31/12/2014 No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>